Abstract 218P
Background
Acute Lymphoblastic Leukemia (ALL) is a disease of rapid cell proliferation. Onset and development of ALL has also been linked to a reduction in the rate of apoptosis. We aimed to study the rate of in vivo spontaneous apoptosis at baseline in predicting induction outcome for newly diagnosed ALL.
Methods
Newly diagnosed ALL, age 1-39 years, were prospectively enrolled during the study period (December 2020- December 2021) and clinical course was followed till end of induction. Whole blood samples were obtained and assessment of Apoptotic Index (AI) was done using two-parameter Flowcytometry by Annexin- Propidium Iodide staining. The AI was expressed as ratio of Annexin V-positive blast cells divided by total blast cells in the gate.
Results
Total of 70 patients were enrolled, median age was 12.5 years (range, 1-39). Baseline characteristics and induction outcomes are summarized in the table. In the entire cohort, median AI in the blasts was 11.89 (0-87). Patients with high risk had a significantly low AI (median=11) compared to standard risk (median AI=16.9): p=0.026. Post induction, patients who attained CR had a significantly high AI (median=11.8) compared to patients with refractory disease (median AI=3.21): p=0.031. A cut-off of 12 was taken to define high AI (>12) and low AI (<12) for analysing post induction outcomes. In patients with high AI(N=28) and low AI(N=35), CR was 100%(n=28/28) and 85%(n=30/35), while refractory disease was 0% vs 14.3%(n=5/35) respectively. Thus, high AI at baseline was significantly associated with attainment of CR(p=0.037). No association of AI was found with baseline characteristics, D8 response and MRD. Table: 218P
Baseline characteristics and Induction outcomes
Characteristics (N=70) | N(%) | |
Age | ||
1-18 years | 49 (70) | |
19-39 years | 21 (30) | |
Gender | ||
Male | 47 (67.1) | |
Female | 23 (32.9) | |
Subtype | ||
B-ALL | 57 (81.4) | |
T-ALL | 13 (18.6) | |
NCI Risk group | ||
HR | 48 (68.6) | |
SR | 22 (31.4) | |
Protocol | ||
BFM-95 | 26 (37) | |
ICiCLe | 44 (63) | |
D8 steroid response | ||
Good response | 55 (78.6) | |
Poor response | 13 (18.6) | |
Unknown (early death) | ||
BM Remission statusCR | 58 (82.9)2 (2.9) | |
Refractory | 5 (7.1) | |
Unknown/death | 7 (10) | |
MRD Positive | 9 (12.9) | |
Negative | 53 (75.7) | |
Unknown | 2 (2.9) | |
Conclusions
Low baseline AI in blast is associated with poor remission rates post induction. Validation of the prognostic role of AI in larger/alternate patient population and for survival outcomes can guide inclusion of apoptosis directed therapy for these high risk subsets.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
JIPMER.
Funding
Indian Council of Medical Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract